Boston Scientific Reports Strong Q2 2025 Growth, Raises Financial Forecast

Boston Scientific, a leading medical technology company, has reported significant growth across multiple segments in the second quarter of 2025, prompting an increase in its financial forecasts for the remainder of the year. The company's performance was marked by notable advancements in medical surgical tools and cardiovascular technologies.

Record-Breaking Revenue and Segment Performance

Boston Scientific logged a 22.8% increase in sales for Q2 2025 compared to the same period last year, pushing its total revenue to over $5 billion. This growth outpaced previous estimates of about 18.5%. The medical surgical tools division, including endoscopy, urology, and neuromodulation tools, saw a 15.7% gain, while the cardiovascular division reported a robust 26.8% increase.

In the urology segment, Boston Scientific experienced a 28.9% increase, driven by double-digit growth in its Rezum water vapor therapy for benign prostatic hyperplasia (BPH). The FDA recently expanded the clearance for this therapy to include larger prostates. However, the overall organic growth in urology was tempered to 6.3% due to the $3.7 billion acquisition of Axonics in November 2024.

Cardiology Innovations Drive Substantial Growth

The cardiology division saw exceptional performance, particularly in electrophysiology. The Farapulse pulsed field ablation system, which received FDA approval in early 2024, generated $1 billion in revenue during its first 12 months on the market. In Q2 2025, electrophysiology sales surged by 96.1% year-over-year, reaching $840 million and becoming cardiology's largest single segment.

Further bolstering its cardiology portfolio, Boston Scientific reported 28.4% growth in its Watchman franchise. This growth was attributed to increased adoption of combining the left atrial appendage closure device with atrial fibrillation ablation in a single procedure to reduce long-term stroke risks. The company also secured CE mark approval in Europe for its latest version, the Watchman FLX Pro.

Strategic Moves and Future Outlook

Despite overall strong performance, Boston Scientific made some strategic decisions during the quarter. In late May, the company withdrew its Acurate family of transcatheter aortic valve replacements from the global market and discontinued pursuit of FDA approval following disappointing clinical study results. This restructuring resulted in an impairment charge of approximately $130 million.

The company also completed two significant acquisitions: SoniVie for $540 million, gaining access to an investigational renal denervation therapy for high blood pressure, and Intera Oncology for $175 million, adding a chemotherapy infusion pump for inoperable liver cancer to its portfolio.

Looking ahead, Boston Scientific has revised its full-year net sales growth forecast to between 18% and 19%, or 14% to 15% organically when accounting for currency fluctuations and recent acquisitions and divestitures. This represents an increase from previous predictions of about 15% to 17%.